Eli Lilly
Q2 2023 Earnings Call
Aug 08, 2023, 9:00 a.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q2 2023 earnings call. [Operator instructions] I would now like to turn the conference over to your host, Joe Fletcher, senior vice president of investor relations. Please go ahead.
Joe Fletcher -- Senior Vice President, Investor Relations
Good morning. Thank you for joining us for Eli Lilly and Company's Q2 2023 earnings call. I'm Joe Fletcher, senior vice president of investor relations. And joining me on today's call are Dave Ricks, Lilly's chair and CEO; Anat Ashkenazi, chief financial officer; Dr.
Dan Skovronsky, chief scientific and medical officer; Anne White, president of Lilly neuroscience; Ilya Yuffa, president of Lilly international; Jake Van Naarden, president of Loxo at Lilly; Mike Mason, president of Lilly diabetes; and Patrik Jonsson, president of Lilly immunology and Lilly USA. We're also joined by Michaela Irons, Mike Springnether, and Lauren Zierki of the investor relations team. During this conference call, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to several factors, including those listed on Slide 3.
Additional information concerning factors that could cause actual results to differ materially is contained in our latest Form 10-K and subsequent forms 10-Q and 8-K filed with the Securities and Exchange Commission. The information we provide about our products and pipeline is for the benefit of the investment community. It's not intended to be promotional and is not sufficient for prescribing decisions. As we transition to our prepared remarks, please note that our commentary will focus on non-GAAP financial measures.
Now I'll turn over the call to Dave.
Dave Ricks -- Chairman and Chief Executive Officer
Thanks, Joe. In the second quarter, Lilly's momentum continued. We advanced our R&D pipeline, progressed our ambitious manufacturing agenda, and delivered strong financial results. Our business saw an acceleration of revenue growth, driven by Mounjaro, Verzenio, and Jardiance.
As base period headwinds from COVID-19 antibody revenue and Alimta's loss of exclusivity recede, we do expect strong growth to continue in the quarters ahead. Lilly has made substantial progress in advancing our pipeline of innovative medicines in recent years, but the past few months have been particularly noteworthy. In early May, we shared the top-line results of the Phase 3 TRAILBLAZER-ALZ 2 trial, which showed donanemab treatment slowed clinical decline in Alzheimer's by 35%. While differences in enrollment criteria and study design make cross-trial comparisons difficult, this represents the greatest percentage cognitive slowing in a primary end point of any disease-modifying Alzheimer's disease treatment reported to date and the only Phase 2 to Phase 3 replication to date.